Trials / Terminated
TerminatedNCT00474695
Study Evaluating Genotypes Using Lucentis
VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
Detailed description
Treatment naive exudative AMD patients will receive Lucentis treatment as standard of care, and followed monthly for 12 months. Standard ophthalmologic exams will be performed, along with ETDRS visual acuity and optical coherence tomography (OCT). A blood sample will be obtained for DNA analysis. The primary outcome measure is change in visual acuity at 4 months after initial Lucentis treatment. Secondary outcomes are change in visual acuity and retinal thickness at 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucentis | 0.05 mg intravitreal injection |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-12-01
- First posted
- 2007-05-17
- Last updated
- 2015-02-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00474695. Inclusion in this directory is not an endorsement.